How mRNA Medicine Will Change the World | Melissa J. Moore | TED 2022.05.18
The secret behind medicine that uses messenger RNA (or mRNA) is that it "teaches" our bodies how to fight diseases on our own, leading to groundbreaking treatments for COVID-19 and, potentially one day, cancer, the flu and other ailments that have haunted humanity for millennia.
RNA researcher Melissa J. Moore -- Moderna's chief scientific officer and one of the many people responsible for the rapid creation and deployment of their COVID-19 vaccine -- takes us down to the molecular level, unraveling how mRNA helps our bodies' proteins maintain health, prevent disease and correct errors in our genetic code. "We have entered an entirely new era of medicine," Moore says.
mRNA (messenger RNA) medicine is a therapeutic technology that uses synthetic strands of genetic material to instruct a patient’s own cells to produce specific proteins.
Instead of introducing a weakened virus or pre-made protein into the body, mRNA acts as a temporary software program.
Key Recent Breakthroughs & Clinical Progress
1. Personalized Cancer Vaccines (Oncology)
The application of mRNA technology in cancer treatment is transitioning from experimental trials to real-world clinical approvals:
- Landmark Phase 3 Melanoma Success: Moderna and Merck announced positive top-line results from their Phase 3 trial testing intismeran (mRNA-4157 / V940) combined with Keytruda for high-risk, post-surgery melanoma.
The combination significantly reduced cancer recurrence and distant spread compared to Keytruda alone, marking the first-ever successful late-stage Phase 3 trial for a personalized mRNA cancer vaccine. - How It Works: A biopsy of the patient's tumor is sequenced to identify unique mutations (neoantigens).
Algorithms design a custom mRNA sequence within weeks to train T cells specifically against that patient's unique tumor markers. - Expanding Solid Tumor Pipeline: Parallel Phase 2/3 trials are evaluating mRNA vaccines for pancreatic, non-small cell lung (NSCLC), renal cell (kidney), and head and neck cancers.
2. Advanced Infectious Disease Vaccines
Building beyond COVID-19, manufacturers are deploying mRNA platforms for broader infectious disease targets:
- Next-Gen Combination Vaccines: Phase 3 trials are testing combination mRNA jabs designed to target Influenza + COVID-19 or RSV + Influenza in a single shot.
- Targeting Complex Pathogens: Early-phase human trials are testing mRNA candidates for HIV, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), and Lyme Disease.
3. In Vivo Gene Editing & Protein Replacement
Beyond traditional vaccines, mRNA is being used as a delivery mechanism for therapeutic proteins and gene-editing tools:
- Transient In Vivo CRISPR Delivery: Rather than using viral vectors, researchers deliver mRNA encoding CRISPR enzymes directly to target organs (like the liver) inside LNPs. Once inside the cell, the mRNA produces the Cas enzyme for temporary, precise gene editing before degrading.
- Rare Genetic Diseases: Trials are underway testing mRNA therapies to restore missing enzymes in patients with metabolic conditions like Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA).
4. Delivery Innovation & LNP Targeted Tropism
A key bottleneck in early mRNA medicine was that lipid nanoparticles naturally accumulated in the liver.
China's biopharmaceutical sector has rapidly built a comprehensive, end-to-end domestic mRNA ecosystem. Driven by regulatory modernization from the National Medical Products Administration (NMPA) and heavy capital investment, China has expanded beyond infectious disease vaccines into personalized oncology, off-the-shelf therapeutic cancer vaccines, and novel delivery platforms.
1. Breakthroughs in Personalized mRNA Cancer Vaccines
Following initial IND (Investigational New Drug) clearances, domestic Chinese biotech firms are accelerating personalized neoantigen mRNA cancer vaccines into human clinical trials:
- LK101 (Likang Life Sciences): Cleared as one of China’s first personalized tumor-specific mRNA vaccines to enter clinical testing. Likang began constructing a dedicated 110 million RMB research and production facility in Beijing targeted for completion in late 2026 to scale patient-specific manufacturing.
- RGL-270 (Ruihongdi Pharma): Received NMPA clearance for clinical trials targeting individualized tumor neoantigens, using AI-driven prediction algorithms to identify patient-specific mutations from sequencing data.
- WGc-043 (West China Hospital / WestGene): Entered clinical use under the special access framework in Hainan’s Boao Lecheng pilot zone. It is a therapeutic vaccine specifically targeting Epstein-Barr Virus (EBV)-related malignancies (such as nasopharyngeal carcinoma).
2. Off-the-Shelf & Universal Cancer mRNA Candidates
To overcome the manufacturing time and high cost of single-patient custom vaccines, Chinese developers are advancing "off-the-shelf" mRNA candidates:
- EVM14 (Everest Medicines): An off-the-shelf therapeutic vaccine encoding five standardized tumor-associated antigens (TAAs) shared across multiple squamous-cell cancers. It obtained dual IND clearances in China and the US, with clinical batches passing release procedures from its Jiashan facility.
- Off-the-Shelf Gastrointestinal & Liver mRNA: Chinese firms (including Abogen Biosciences and Stemirna Therapeutics) are leveraging mRNA constructs encoding shared target antigens for hepatocellular carcinoma (HCC) and gastric cancers to provide readily available treatments for high-prevalence local oncology indications.
3. Regulatory Acceleration & Manufacturing Ecosystem
- NMPA 30-Day Accelerated Channels: The NMPA implemented streamlined 30-day IND review pathways for high-priority innovative biologics, drastically reducing the time required to move novel mRNA candidates from pre-clinical optimization into Phase 1 clinical trials.
- Domestic Supply Chain Independence: Chinese biotechs have significantly reduced reliance on Western suppliers for key raw materials—developing domestic supplies for 5' capping analogs, modified nucleosides, and proprietary lipid nanoparticles (LNPs), alongside scaled enzyme synthesis facilities.
4. Next-Generation Delivery & Non-Vaccine Therapeutics
- In Vivo Gene Editing & Protein Replacement: Chinese academic institutions and biotech startups are deploying mRNA to deliver CRISPR/Cas enzymes and base-editing systems directly to the liver and blood cells in vivo, avoiding complex ex vivo cellular manipulation.
- Targeted LNPs (tLNPs): Local research teams are optimizing targeted lipid nanoparticles capable of extrahepatic delivery (e.g., directing mRNA selectively to pulmonary tissue, tumor microenvironments, or specific immune cell subsets), expanding mRNA usage into metabolic and autoimmune conditions.
Overview of Leading Chinese mRNA Programs
| Candidate / Platform | Developer | Therapeutic Focus | Primary Technological Milestone |
| LK101 | Likang Life Sciences | Personalized Solid Tumors | First domestic personalized neoantigen mRNA vaccine in clinical trials; dedicated Beijing production hub. |
| EVM14 | Everest Medicines | Squamous Cell Cancers | Off-the-shelf therapeutic vaccine encoding 5 shared TAAs; dual China/US IND clearances. |
| WGc-043 | West China Hospital / WestGene | EBV-Related Malignancies | Therapeutic vaccine targeting EBV-driven cancers; deployed under Hainan Boao special access framework. |
| RGL-270 | Ruihongdi Pharma | Neoantigen Oncology | NMPA-cleared personalized cancer vaccine powered by proprietary AI antigen-prediction pipelines. |
| SYS6006 / Abogen Platform | CSPC / Abogen Biosciences | Infectious Diseases & Solid Tumors | Fully commercialized domestic LNP-mRNA production lines supporting multi-target oncology pipelines. |
This news report highlights the National Medical Products Administration's accelerated regulatory approvals for innovative biopharmaceuticals, illustrating the broader regulatory and clinical ecosystem in China that supports new mRNA and advanced drug therapies.
You May Like:
No comments:
Post a Comment